Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Ltd has announced the quotation of 2,322 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing operations, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates in the medical industry, focusing on the development and commercialization of innovative medical devices. The company’s primary product is a targeted radioactive implant designed for the treatment of pancreatic and liver cancer, aiming to improve patient outcomes in these challenging areas.
Average Trading Volume: 41,049
Technical Sentiment Signal: Sell
Current Market Cap: A$22.78M
Learn more about OSL stock on TipRanks’ Stock Analysis page.